See more : Hopson Development Holdings Limited (0754.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Grapefruit USA, Inc. (GPFT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Grapefruit USA, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Southwestern Energy Company (SWN) Income Statement Analysis – Financial Results
- Marshall Monteagle PLC (MMP.JO) Income Statement Analysis – Financial Results
- Bionomics Limited (BNOEF) Income Statement Analysis – Financial Results
- Cielo Waste Solutions Corp. (CMC.V) Income Statement Analysis – Financial Results
- Nexi S.p.A. (NEXI.MI) Income Statement Analysis – Financial Results
Grapefruit USA, Inc. (GPFT)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.grapefruitblvd.com
About Grapefruit USA, Inc.
Grapefruit USA, Inc. operates as a manufacturer and distributor of cannabis products in California. It primarily provides Hourglass, a time release THC+CBD-infused topical cream through online store. The company was formerly known as Grapefruit Boulevard Investments, Inc. and changed its name to Grapefruit USA, Inc. in January 2020. Grapefruit USA, Inc. was founded in 2017 and is based in Wilmington, Delaware.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 200.00 | 39.79K | 588.96K | 3.67M | 451.20K | 181.50K | 41.83K | 33.08K | 220.81K | 398.27K | 1.05M | 1.05M | 1.07M | 1.18M | 1.36M | 1.76M | 1.32M | 1.39M | 2.10M | 1.28M |
Cost of Revenue | 237.11K | 504.03K | 1.12M | 3.39M | 708.57K | 183.46K | 14.26K | 10.25K | 169.12K | 163.14K | 585.79K | 585.79K | 505.87K | 532.16K | 700.25K | 662.23K | 910.13K | 676.62K | 1.07M | 638.11K |
Gross Profit | -236.91K | -464.25K | -530.17K | 280.47K | -257.37K | -1.96K | 27.57K | 22.84K | 51.69K | 235.14K | 466.75K | 466.75K | 562.75K | 645.32K | 664.64K | 1.09M | 413.65K | 709.32K | 1.02M | 642.55K |
Gross Profit Ratio | -118,456.00% | -1,166.86% | -90.02% | 7.64% | -57.04% | -1.08% | 65.90% | 69.03% | 23.41% | 59.04% | 44.34% | 44.34% | 52.66% | 54.81% | 48.70% | 62.28% | 31.25% | 51.18% | 48.81% | 50.17% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 2.40K | 108.79K | 200.69 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 1.78M | 1.32M | 1.62M | 6.32M | 1.65M | 2.70M | 1.50M | 1.36M | 1.86M | 1.86M | 0.00 | 2.47M | 2.51M | 2.28M | 2.47M | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 7.66K | 169.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 688.91K | 1.73M | 1.79M | 1.49M | 1.62M | 6.32M | 1.65M | 2.70M | 1.50M | 1.36M | 1.86M | 1.86M | 2.95M | 2.47M | 2.51M | 2.28M | 2.47M | 2.75M | 1.63M | 1.92M |
Other Expenses | 0.00 | 0.00 | 371.32K | 169.35 | 0.00 | -23.33K | 87.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 688.91K | 1.73M | 1.79M | 1.49M | 1.62M | 6.32M | 1.65M | 2.70M | 1.50M | 1.36M | 1.86M | 1.86M | 2.95M | 2.47M | 2.51M | 2.28M | 2.47M | 3.01M | 2.18M | 2.66M |
Cost & Expenses | 926.02K | 2.23M | 2.91M | 4.88M | 2.33M | 6.32M | 1.67M | 2.71M | 1.67M | 1.52M | 2.45M | 2.45M | 3.45M | 3.00M | 3.21M | 2.94M | 3.38M | 3.69M | 3.25M | 3.30M |
Interest Income | 0.00 | 0.00 | 1.68K | 2.10K | 571.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 1.11M | 1.47M | 1.68M | 2.10M | 571.05K | 679.69K | 1.17M | 2.89M | 1.19M | 6.06K | -975.99K | 975.99K | 423.37K | 55.15K | 52.37K | 51.79K | 70.86K | 68.78K | 85.84K | 78.12K |
Depreciation & Amortization | 186.72K | 73.61K | 741.60K | 171.06K | 63.98K | 24.71K | 3.40M | 1.00 | 0.00 | 0.00 | 0.00 | 7.57K | 10.52K | 7.82K | -3.10K | 17.91K | 15.23K | 14.62K | 15.23K | 16.39K |
EBITDA | -549.06K | -2.23M | -3.08M | -1.21M | -3.96M | -243.61K | 4.03M | -3.87M | -1.44M | -1.11M | -6.51M | 3.62M | -17.49M | -4.14M | -1.86M | -836.43K | -2.05M | -2.29M | -1.14M | -2.00M |
EBITDA Ratio | -274,528.00% | -5,330.14% | -110.77% | -28.19% | -401.68% | -3,495.76% | -3,680.43% | -8,084.79% | -657.31% | -281.19% | -132.57% | -131.85% | -222.14% | -154.04% | -135.15% | -66.48% | -158.52% | -164.31% | -29.14% | -111.43% |
Operating Income | -925.82K | -2.19M | -2.42M | -1.21M | -1.88M | -6.32M | -1.63M | -2.67M | -1.45M | -1.12M | -1.40M | -1.40M | -2.38M | -1.92M | -1.93M | -1.19M | -2.05M | -2.30M | -1.16M | -2.02M |
Operating Income Ratio | -462,911.00% | -5,515.16% | -410.14% | -32.85% | -415.86% | -3,482.91% | -3,889.59% | -8,084.79% | -657.31% | -281.19% | -132.57% | -132.57% | -223.13% | -163.16% | -141.24% | -67.50% | -154.99% | -165.95% | -55.19% | -157.44% |
Total Other Income/Expenses | -924.14K | -1.58M | -3.09M | -2.85M | -2.72M | 5.96M | 4.48M | -4.09M | -1.18M | 524.00 | -5.13M | 4.03M | -15.54M | -2.28M | 16.45K | 279.07K | -8.81K | 178.83K | -62.13K | 99.89K |
Income Before Tax | -1.85M | -3.78M | -5.51M | -4.06M | -4.60M | -8.13M | 2.85M | -6.76M | -2.63M | -1.12M | 800.00 | 2.64M | -17.93M | -4.20M | -1.91M | -906.13K | -2.06M | -2.12M | -1.22M | -1.92M |
Income Before Tax Ratio | -924,981.50% | -9,492.70% | -934.71% | -110.47% | -1,019.42% | -4,478.93% | 6,821.37% | -20,435.48% | -1,191.81% | -281.06% | 0.08% | 250.56% | -1,677.49% | -356.68% | -140.03% | -51.61% | -155.65% | -153.05% | -58.16% | -149.64% |
Income Tax Expense | 2.00 | 0.00 | 1.68M | -753.70 | 580.52K | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 |
Net Income | -1.85M | -3.78M | -7.19M | -4.06M | -5.18M | -8.13M | 2.85M | -6.76M | -2.63M | -1.12M | 2.64M | 2.64M | -17.93M | -4.20M | -1.91M | -906.93K | -2.06M | -2.12M | -1.22M | -1.92M |
Net Income Ratio | -924,981.50% | -9,492.70% | -1,220.69% | -110.47% | -1,148.08% | -4,479.37% | 6,819.46% | -20,437.90% | -1,192.18% | -281.26% | 250.49% | 250.49% | -1,677.56% | -356.75% | -140.09% | -51.65% | -155.71% | -153.10% | -58.19% | -149.70% |
EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.04 | -0.25 | 0.21 | -0.64 | -0.29 | -0.15 | 0.02 | 0.20 | -0.91 | -0.22 | -0.13 | -0.07 | -0.19 | -0.22 | -0.14 | -0.25 |
EPS Diluted | 0.00 | -0.01 | -0.01 | -0.01 | -0.04 | -0.25 | 0.18 | -0.64 | -0.29 | -0.15 | 0.02 | 0.07 | -0.91 | -0.22 | -0.13 | -0.07 | -0.19 | -0.22 | -0.14 | -0.25 |
Weighted Avg Shares Out | 901.40M | 670.66M | 515.34M | 498.23M | 140.04M | 32.12M | 13.83M | 10.64M | 9.20M | 7.49M | 149.75M | 25.00M | 19.63M | 18.84M | 14.73M | 12.18M | 10.60M | 9.72M | 8.53M | 7.76M |
Weighted Avg Shares Out (Dil) | 901.40M | 670.66M | 515.34M | 498.23M | 140.04M | 32.12M | 15.67M | 10.64M | 9.20M | 7.49M | 149.75M | 37.50M | 19.63M | 18.84M | 14.73M | 12.18M | 10.60M | 9.72M | 8.53M | 7.76M |
Canna-Biotech Co. Grapefruit USA Signs Term Sheet With Dubai-Based Lender To Build GPFT 'Mothership'
Grapefruit USA, Inc. Announces Expanded Agreement with Canadian Firms Medz Cannabis and 6PAK Solutions to Shepherd Grapefruit's Patented Hourglass™ Time Release THC+CBD Delivery Cream Through Health Canada's Regulatory Process
Grapefruit USA, Inc. Acquires Controlling Interest in Summit Boys, Inc. of Monterey, Calif., in Stock-for-Stock Exchange
Grapefruit USA, Inc. Issues Further Update Concerning Formation of Joint Venture with Canadian Partner to Distribute Hourglass Products in Canada, Possible Acquisition
Grapefruit Clarifies Potential Ramifications of Senate Majority Leader Schumer's Push to Federally Legalize Cannabis
Captor Capital's California Retail Cannabis Dispensaries to Carry Grapefruit's Patented Hourglass THC/CBD Delivery Cream
Grapefruit USA, Inc. Announces New Strategic Alliance with 6PAK Solutions Canada to Shepherd Grapefruit's Patented Hourglass™ Time Release THC+CBD Delivery Cream through Health Canada's Regulatory Requirements
Grapefruit USA, Inc. Expands Its Hemp Based CBD Products with a New USDA Certified Organic CBD Pet Tincture
Grapefruit USA, Inc. Issues Update Concerning the Company's Progress Through the First Five Months of 2021
Grapefruit USA Retains Premier Investor Relations and Communications Marketing Firm SRAX to Raise Its Brand Awareness
Source: https://incomestatements.info
Category: Stock Reports